Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.53 |
| ▸ | MEN1 | O00255 | 6/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.53 |
| ▸ | GAA | P10253 | 6/20 | 0.53 |
| ▸ | LMNA | P02545 | 5/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | PIKFYVE | Q9Y2I7 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.45 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.45 |
| ▸ | APAF1 | O14727 | 1/20 | 0.45 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10196654 | 1.00 | MAPT (0.53) | MAPTMEN1KMT2AGAALMNA | |
| SCHEMBL428754 | 1.00 | MAPT (0.53) | MAPTMEN1KMT2AGAALMNA | |
| SCHEMBL13758963 | 0.92 | MAPT (0.53) | MAPTMEN1KMT2AGAALMNA | |
| SCHEMBL428707 | 0.89 | MAPT (0.51) | MAPTMEN1KMT2AGAALMNA | |
| SCHEMBL10196334 | 0.89 | MAPT (0.51) | MAPTMEN1KMT2AGAALMNA | |
| SCHEMBL428706 | 0.89 | MAPT (0.51) | MAPTMEN1KMT2AGAALMNA | |
| SCHEMBL1721328 | 0.88 | MAPT (0.50) | MAPTMEN1KMT2AGAALMNA | |
| SCHEMBL1721324 | 0.88 | MAPT (0.50) | MAPTMEN1KMT2AGAALMNA | |
| SCHEMBL428888 | 0.87 | PIKFYVE (0.51) | MAPTMEN1KMT2AGAALMNA | |
| SCHEMBL10196651 | 0.87 | PIKFYVE (0.51) | MAPTMEN1KMT2AGAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1458687-B1 | PYRIMIDINE COMPOUNDS AS INTERLEUKIN-12 (IL-12) INHIBITORS | SYNTA PHARMACEUTICALS CORP (US) | 2012-01-11 | — | — | EP | claimed |
| US-20100120722-A1 | HETEROCYCLIC COMPOUNDS FOR PREVENTING AND TREATING DISORDERS ASSOCIATED WITH EXCESSIVE BONE LOSS | SYNTA PHARMACEUTICALS CORP. (US) | 2010-05-13 | — | — | US | claimed |
| US-20080058297-A1 | Heterocyclic Compounds For Preventing And Treating Disorders Associated With Excessive Bone Loss | SYNTA PHARMACEUTICALS CORP. (US) | 2008-03-06 | — | — | US | claimed |
| EP-1626725-A2 | HETEROCYCLIC COMPOUNDS FOR PREVENTING AND TREATING DISORDERS ASSOCIATED WITH EXCESSIVE BONE LOSS | Synta Pharmaceuticals Corporation (US) | 2006-02-22 | — | — | EP | claimed |
| EP-1458687-A4 | PYRIMIDINE COMPOUNDS | SYNTA PHARMACEUTICALS CORP (US) | 2005-03-23 | — | — | EP | claimed |
| WO-2005000404-A2 | HETEROCYCLIC COMPOUNDS FOR PREVENTING AND TREATING DISORDERS ASSOCIATED WITH EXCESSIVE BONE LOSS | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-01-06 | — | — | WO | claimed |
| EP-1458687-A2 | PYRIMIDINE COMPOUNDS | Synta Pharmaceuticals Corporation (US) | 2004-09-22 | — | — | EP | claimed |
| WO-2003047516-A2 | PYRIMIDINE COMPOUNDS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2003-06-12 | — | — | WO | claimed |
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP (US) | 2015-06-25 | — | — | US | disclosed |
| US-20120021434-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-01-26 | — | — | US | disclosed |
| EP-1458687-B1 | PYRIMIDINE COMPOUNDS AS INTERLEUKIN-12 (IL-12) INHIBITORS | SYNTA PHARMACEUTICALS CORP (US) | 2012-01-11 | — | — | EP | disclosed |
| US-20110288081-A1 | PYRIMIDINE COMPOUNDS AND USES THEREOF | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110098267-A1 | TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-04-28 | — | — | US | disclosed |
| US-7851466-B2 | Pyrimidine compounds and uses thereof | SYNTA PHARMACEUTICALS CORP. (US) | 2010-12-14 | — | — | US | disclosed |
| EP-1458687-A4 | PYRIMIDINE COMPOUNDS | SYNTA PHARMACEUTICALS CORP (US) | 2005-03-23 | — | — | EP | disclosed |
| EP-1458687-A2 | PYRIMIDINE COMPOUNDS | Synta Pharmaceuticals Corporation (US) | 2004-09-22 | — | — | EP | disclosed |
| US-20040048873-A1 | Pyrimidine compounds | SYNTA PHARMACEUTICALS CORP., A DELAWARE CORPORATIO | 2004-03-11 | — | — | US | disclosed |
| US-6693097-B2 | Pyrimidine compounds | SYNTA PHARMACEUTICALS CORP. | 2004-02-17 | — | — | US | disclosed |
| US-20030139403-A1 | Pyrimidine compounds | SHIONOGI BIORESEARCH CORP. | 2003-07-24 | — | — | US | disclosed |
| WO-2003047516-A2 | PYRIMIDINE COMPOUNDS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098267-A1 | TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS | IL17A, IL23R, IL15 | MAPT 238/4885MEN1 4796/4885KMT2A 4300/4885 |
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | REL, NFATC1, BCL6 | MAPT 4316/4885MEN1 3751/4885KMT2A 1509/4885 |
| US-20080058297-A1 | Heterocyclic Compounds For Preventing And Treating Disorders Associated With Excessive Bone Loss | BRCA1, VHL, ESR1 | MAPT 1747/4885MEN1 149/4885KMT2A 2431/4885 |
| US-20100120722-A1 | HETEROCYCLIC COMPOUNDS FOR PREVENTING AND TREATING DISORDERS ASSOCIATED WITH EXCESSIVE BONE LOSS | BRCA1, VHL, ESR1 | MAPT 1747/4885MEN1 149/4885KMT2A 2431/4885 |
| US-20110288081-A1 | PYRIMIDINE COMPOUNDS AND USES THEREOF | RORC, IL23R, ORC3 | MAPT 4267/4885MEN1 4837/4885KMT2A 4103/4885 |
| US-20030139403-A1 | Pyrimidine compounds | CBR1, CBR3, CCNO | MAPT 4042/4885MEN1 4719/4885KMT2A 2347/4885 |
| US-20040048873-A1 | Pyrimidine compounds | CBR1, CBR3, CCNO | MAPT 4185/4885MEN1 4656/4885KMT2A 2687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.